What Biomere does

Biomere is a US-based preclinical contract research organization (CRO) founded in 1996 as a spin-out from the University of Massachusetts Medical School and headquartered in Worcester, Massachusetts. The company specializes in non-GLP pharmacokinetic/pharmacodynamic (PK/PD) studies and early toxicology using in vivo small and large animal models, including rodents, rabbits, and non-human primates. It operates a 100,000 sq ft AAALAC-accredited, OLAW-assured, DEA-licensed, and USDA-registered facility described as the largest NHP laboratory in New England, and runs roughly 350 rodent and 100 large animal studies per year with a stated >95% client retention rate.

Its service portfolio spans eight integrated lines: gene therapy PK/PD (AAV, LNP, oligonucleotide, mRNA, siRNA, CRISPR), ocular disease models and dosing, general PK/PD characterization, colony management for genetically modified mice, laboratory sciences (flow cytometry, multiplex MSD, qPCR, clinical chemistry, LC-MS), surgical services (CSF catheterization, ICM/ICV dosing, specialty biopsies), disease models across metabolic, oncology, autoimmune, and CNS areas, and therapeutic-area dosing expertise. Biomere maintains a multi-channel commercial motion combining enterprise field sales, marketplace storefronts on Scientist.com and ScienceExchange, scientific content marketing (The Exchange podcast, webinars, posters at SOT/ARVO/ASGCT/ACT), and a private life-science community called The Concourse. Partnerships with SauveBio (flow cytometry), Splice Histology (histology), and Emulate Inc. (Organ-Chip) extend the offering toward an integrated, single-vendor preclinical data package.

Biomere was acquired by JOINN Laboratories, the largest public nonclinical CRO in China, in 2019, and now operates as a wholly-owned subsidiary within JOINN's global network of facilities in the US (Worcester, Richmond CA) and China (Suzhou, Beijing, Wuzhou, Chongqing, Guangzhou). The economic model is fee-for-service professional services revenue with custom quote-based pricing and multi-year engagements; revenue is not publicly disclosed. A planned 2026 launch of Organ-Chip services via Emulate represents a deliberate extension of the platform beyond traditional in vivo work.

Name

Biomere

Legal name

Biomere

Website

https://biomere.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

101–250 employees

Short description

Biomere is a US preclinical CRO (Worcester, MA) acquired by China's JOINN Laboratories in 2019, providing non-GLP PK/PD and early toxicology in vivo studies in rodents and NHPs to pharma, biotech, and academic clients.

Ownership category

akta.pro rank

Product category

Preclinical Contract Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industries

Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

Keywords

• Preclinical CRO services
• Pharmacokinetic studies
• Early toxicology testing
• Non-human primate research
• Animal model services

Headquarters

HQ city

Worcester

HQ country

United States

HQ region

North America

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Preclinical Contract Research Services: Biomere generates revenue through fee-for-service preclinical contract research engagements. Clients engage Biomere to conduct non-GLP PK/PD studies, early toxicology studies, and related endpoint analysis across small and large animal models. Pricing is project-based and quote-driven, varying by study complexity, species, number of endpoints, and duration.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

Biomere is a Boston-area preclinical contract research organization (CRO) that delivers non-GLP pharmacokinetic/pharmacodynamic (PK/PD) and early toxicology studies in rodent, large animal, and non-human primate models. The company operates extensive AAALAC-accredited vivarium space and integrated laboratory sciences (flow cytometry, MSD multiplex assays, qPCR, clinical chemistry) to generate endpoint data packages that support go/no-go decisions and the transition from lead optimization to IND-enabling studies.

Product overview

Biomere is a preclinical Contract Research Organization (CRO) offering a portfolio of integrated services rather than a single software product. The core service offering includes PK/PD Characterization, Gene Therapy PK/PD, Ocular Disease Models, Laboratory Sciences (endpoint analysis), Colony Management Solutions, Surgical Services, Disease Models, and Therapeutic Area Expertise. These services are designed to work together as an end-to-end preclinical drug development offering, where clients can run dosing, sample collection, and downstream endpoint analysis under a single CRO, supporting the transition from lead optimization to IND-enabling studies.

Differentiator

Problem solved

Functional benefit

Products and services

• Gene Therapy PK/PD
• Ocular Disease Models and PK/PD
• PK/PD Characterization Services
• Laboratory Sciences
• Colony Management Solutions
• Surgical Services
• Disease Models
• Therapeutic Area Expertise
• Organ-Chip Services

Quantifiable outcome

• >95% client retention rate
• +4 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Three partnerships are on record, tiered flagship and core.

• JOINN Laboratories (Parent Company)flagshipStrategic or Co-development Partner · 1 January 2019JOINN Laboratories, the largest public nonclinical CRO in China, acquired Biomere in 2019. This acquisition created a globally integrated drug development CRO service offering. Biomere's non-GLP PK/PD and early toxicology services complement JOINN's full GLP toxicology and clinical trial support capabilities, enabling seamless program progression from discovery through IND-enabling studies. JOINN has facilities in Suzhou, Beijing, Wuzhou, Chongqing, and Guangzhou in China, and Richmond CA in the US.
• SauveBiocoreTechnology or IntegrationBiomere and SauveBio announced a partnership combining Biomere's in vivo PK/PD and early toxicology expertise with SauveBio's flow cytometry and cell sorting capabilities. This collaboration delivers comprehensive data packages to support program needs and help clients make critical go/no-go decisions. SauveBio provides high-fidelity cell sorting for applications including rare immune subset isolation, single-cell RNA sequencing quality control, and GFP+ cell sorting for gene therapy vector validation.
• Splice HistologycoreTechnology or IntegrationBiomere partnered with Splice Histology to combine Biomere's in vivo PK/PD and early toxicology expertise with Splice Histology's full-service histology services. Splice Histology is a veteran and locally owned company supporting hospitals and biotechs with pre-diagnostic and preclinical workflow histology services. The partnership results in complete preclinical data packages for go/no-go decisions.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Emulate Inc. Emulate develops Organ-Chip (microphysiological) technology for preclinical testing, including Liver-Chip and Kidney-Chip applications. It is comparable to Biomere as a partner and partial substitute, providing an in vitro alternative to certain in vivo preclinical studies.

Direct peers

• Inotiv: Inotiv is a US-focused preclinical CRO and research models provider offering in vivo safety assessment, PK/PD, and toxicology services. It is one of the closest direct competitors to Biomere in the mid-sized US preclinical CRO segment, particularly for rodent and NHP work.
• JOINN Laboratories: JOINN is Biomere's parent and the largest nonclinical CRO in China, offering GLP toxicology and clinical support. It is the most directly comparable peer, with overlapping service lines and a footprint (China plus Richmond, CA) that overlaps Biomere's offering.
• Pharmaron: Pharmaron is a China-origin CRO/CDMO with integrated preclinical drug discovery and in vivo PK/PD, bioanalysis, and safety assessment services. It is comparable to Biomere in its preclinical CRO positioning and global service mix, particularly for US and Asia-based sponsors.
• Frontage Laboratories: Frontage is a US-headquartered CRO providing preclinical and bioanalytical services including in vivo PK/PD, toxicology, and bioanalysis. It is comparable to Biomere in service mix and customer base among small and mid-cap biopharma sponsors.

Broad incumbents

• Eurofins Scientific: Eurofins operates a global network of laboratory testing and contract research services including preclinical and bioanalytical offerings. It is a broad incumbent comparable to Biomere in the bioanalytical and laboratory sciences portion of the workflow.
• WuXi AppTec: WuXi AppTec is a global CRO/CDMO with preclinical, bioanalytical, and biologics capabilities including in vivo PK/PD and toxicology. It competes with Biomere for US and global preclinical engagements and is a key comparable for nonclinical service scale and breadth.
• Charles River Laboratories: Charles River is the largest preclinical CRO globally with extensive in vivo PK/PD, toxicology, and research models services spanning rodents and NHPs. It directly competes with Biomere for preclinical PK/PD and safety assessment work and is the benchmark incumbent in the same category.
• Labcorp (Covance): Labcorp's Covance segment operates a global preclinical and clinical CRO with full GLP toxicology, PK/PD, and bioanalytical capabilities. It competes with Biomere across early-stage in vivo studies and offers the larger, integrated alternative that sponsors often consolidate toward.

Regional players

• Shanghai Medicilon: Medicilon is a China-based preclinical CRO offering in vivo PK/PD, toxicology, and bioanalytical services with a US presence. It is comparable to Biomere in preclinical service scope, particularly for sponsors seeking China-based execution and IND-enabling support.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/brmcro
• LinkedInlinkedin.com/company/biomedical-research-models-inc-

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biomere